Posttransfer support for the transfer of one cryopreserved embryo at the blastocyst stage

• Sergey V. Nikitin
• Mariya P. Grishchuk
• Lubov G. Dokaeva
• Svetlana S. Paskar
• Irina S. Chernen’kaya

Abstract

Background. The article presents the results of a comparative analysis of protocols for preparing the endometrium for the transfer of thawed embryos against the background of hormone replacement therapy.

Aim of the study – to compare the effectiveness and safety of oral dydrogesterone compared with vaginal micronized progesterone in post-transfer support cycles during the transfer of a single cryopreserved embryo at the blastocyst stage.

Material and methods. A retrospective comparative study included 259 patients aged 25 to 45 years who underwent the transfer of one own thawed embryo in a cycle of hormone replacement therapy for the period from January to December 2022 in the Department of Reproductology of the Mother and Child Clinic, St. Petersburg. The patients were divided into 2 groups for complete secretory transformation of the endometrium: group 1 (n=145) used dydrogesterone at a dose of 30 mg/day, group 2 (n=114) – micronized vaginal progesterone (MVP) at a dose of 600 mg/day. The primary endpoint was the rate of clinical pregnancy, the secondary endpoint was the rate of ongoing pregnancy at 12 weeks. In cases of ongoing and ongoing pregnancy, support with gestagens continued up to 20 weeks.

Results. Efficiency rates in the group using dydrogesterone were significantly higher, but the data did not reach statistical significance. The clinical frequency in group 1 (dydrogesterone) amounted to 53.8% (78/145), in group 2 (MVP) – 43.9% (50/114) however, p>0.05. The frequency of ongoing pregnancy at 12 weeks of gestation is group 1 was 51.7% (75/145) versus 41.2% (47/114), p>0.05.

Conclusion. The results of the study showed that dydrogesterone is a suitable option for supporting LF in cycles with the transfer of thawed embryos and can help achieve higher rates of clinical and ongoing pregnancy compared to vaginal micronized progesterone. Dydrogesterone can be recommended as a drug of choice in supporting the post-transfer period in cycles with the transfer of a thawed embryo.

Keywords: cryopreserved embryo; post-transfer support cycle; hormone replacement therapy; dydrogesterone

References

1. Russian Association of Human Reproduction. Register of ART of Russia. Report for 2021. (in Russian)

2. Resolution of the Advisory Board on the subject: Multicenter Open-Label Observational Program to Research on Predictors of Pregnancy Rate in Assisted Reproductive Technology in the Russian Population According to Actual International and National Guidelines (IRIS study). Akusherstvo i ginekologiya [Obstetrics and Gynecology] 2019; (12): 218–25. DOI: https://doi.org/10.18565/aig.2019.12.218-225 (in Russian)

3. Bashmakova N.V., Lokshin V.N., Isenova S.Sh., Khramtsova A.Yu., Dan’kova I.V., Ryabukhin I.V. Comparative analysis of the effectiveness of programs and perinatal outcomes after frozen-thawed embryo transfer depending on post-transfer support medications. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2023; (7): 103–8. DOI: https://doi.org/10.18565/aig.2023.161 (in Russian)

4. Bosch E., Broer S., Griesinger G., Grynberg M., Humaidan P., Kolibianakis E., et al. ESHRE guideline: ovarian stimulation for IVF/ICSI (translated into Russian under the editorship of Prof. V.S. Korsak). Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2021; 9 (2): 34–51. (in Russian)

5. Doblinger J., Cometti B., Trevisan S., Griesinger G. Subcutaneous progesterone is effective and safe for luteal phase support in IVF: an individual patient data meta-analysis of the phase III trials. PLoS One. 2016; 11 (3): e0151388. Epub 2016 Mar 19. DOI: https://doi.org/10.1371/journal.pone.0151388 PMID: 26991890; PMCID: PMC4798618.

6. Khrouf M., Slimani S., Khrouf M.R., Braham M., Bouyahia M., Berjeb K.K., et al. Progesterone for luteal phase support in in vitro fertilization: comparison of vaginal and rectal pessaries to vaginal capsules: a randomized controlled study. Clin Med Insights Womens Health. 2016; 9: 43–7. DOI: https://doi.org/10.4137/CMWH.S32156 Epub 2017 Jan 18. PMID: 28096703; PMCID: PMC5217976.

7. Vaisbuch E., Leong M., Shoham Z. Progesterone support in IVF: is evidence-based medicine translated to clinical practice? A worldwide web-based survey. Reprod Biomed Online. 2012; 25 (2): 139–45. DOI: https://doi.org/10.1016/j.rbmo.2012.04.005 PMID: 22683150.

8. Gallyamova E.M., Perminova S.G., Durinyan E.R., Mityurina E.V Current approaches to luteal phase management in an in-vitro fertilization program. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2014; (1): 15–22. (in Russian)

9. Shikh E.V. Pharmacotherapy during pregnancy. Moscow, 2020. (in Russian)

10. Female infertility. Clinical recommendations of ROAG. Moscow, 2019: 117 p. (in Russian)

11. Shoham G., Leong M., Weissman A. A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys. Reprod Biol Endocrinol. 2021; 19 (1): 15. DOI: https://doi.org/10.1186/s12958-021-00696-2

12. Patki A. Role of dydrogesterone for luteal phase support in assisted reproduction. Reprod Sci. 2024; 31 (1): 17–29. DOI: https://doi.org/10.1007/s43032-023-01302-z

13. Bespalova O.N., Butenko M.G., Bakleycheva M.O., Kosyakova O.V., Sargsyan G.S., Kogan I.Yu. Efficacy of progestogens in the management of threatened miscarriage in women with multiple pregnancies resulting from assisted reproductive technologies. Voprosy ginekologii, akusherstva i perinatologii [Problems of Gynecology, Obstetrics and Perinatology]. 2021; 20 (1): 47–54. DOI: https://doi.org/10.20953/1726-1678-2021-1-47-54 (in Russian)

14. Sabirova V.L., Kurbatina M.M., Minnullina F.F., Filyushina A.V. Comparative analysis of the efficacy and safety of gestagens for luteal phase support in fresh IVF/ICSI cycles with single embryo transfer. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2023; 22 (6): 28–35. DOI: https://doi.org/10.20953/1726-1678-2023-6-28-35 (in Russian)

15. Ozer G., Yuksel K.B., Yucel Cicek O.S., Kahraman S. Oral dydrogesterone vs micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. J Gynecol Obstet Hum Reprod. 2021; 50 (5): 10203. DOI: https://doi.org/10.1016/j.jogoh.2020.102030

16. Vuong L.N., Pham T.D., Le K.T.Q., Ly T.T., Le H.L., Nguyen D.T.N., et al. Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Hum Reprod. 2021; 36 (7): 1821–31. DOI: https://doi.org/10.1093/humrep/deab093 PMID: 33930124.

17. du Boulet B., Ranisavljevic N., Mollevi C., Bringer-Deutsch S., Brouillet S., Anahory T. Individualized luteal phase support based on serum progesterone levels in frozen-thawed embryo transfer cycles maximizes reproductive outcomes in a cohort undergoing preimplantation genetic testing. Front Endocrinol (Lausanne). 2022; 13: 1051857. DOI: https://doi.org/10.3389/fendo.2022.1051857 PMID: 36531476; PMCID: PMC9755854.

18. Vidal A., Dhakal C., Werth N., Weiss J.M., Lehnick D., Kohl Schwartz A.S. Supplementary dydrogesterone is beneficial as luteal phase support in artificial frozen-thawed embryo transfer cycles compared to micronized progesterone alone. Front Endocrinol. 2023; 14: 1128564. DOI: https://doi.org/10.3389/fendo.2023.1128564

19. Sabirova V.L., Minnullina F.F., Kurbatina M.M. The effectiveness of various options for preparing the endometrium against the background of hormone replacement therapy for a thawed embryo transfer program. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2024; 12 (2): 59–64. DOI: https://doi.org/10.33029/2303-9698-2024-12-2-59-64 (in Russian)

20. Syrkasheva A.G., Petrosyan Ya.A., Dolgushina N.V. Gestagens in assisted reproductive technology programs. Ginekologiya [Gynecology]. 2019; 21 (2): 76–9. DOI: https://doi.org/10.26442/20795696.2019.2.190238 (in Russian)

21. Metello J., Tomas C., Ferreira P., Santos-Ribeiro S. The Addition of Dydrogesterone after Frozen Embryo Transfer in Hormonal Substituted Cycles with Low Progesterone Levels [Uso adicional de didrogesterona após transferência de blastocisto em ciclos substituídos com valores baixos de progesterona]. Rev Bras Ginecol Obstet. 2022; 44 (10): 930–37. DOI: https://doi.org/10.1055/s-0042-1751058

22. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., et al. Classification and pharmacology of progestins. Maturitas. 2003; 46 (suppl 1): S7–16. DOI: https://doi.org/10.1016/j.maturitas.2003.09.014 Epub 2003 Dec 13. PMID: 14670641.

23. Colombo D., Ferraboschi P., Prestileo P., Toma L. A comparative molecular modeling study of dydrogesterone with other progestational agents through theoretical calculations and nuclear magnetic resonance spectroscopy. J Steroid Biochem Mol Biol. 2006; 98 (1): 56–62. DOI: https://doi.org/10.1016/j.jsbmb.2005.07.009 Epub 2005 Oct 12. PMID: 16216490.

24. Griesinger G., Blockeel C., Kahler E., Pexman-Fieth C., Olofsson J.I., Driessen S., et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: a systematic review and individual participant data meta-analysis. PLoS One. 2020; 15 (11): e0241044. DOI: https://doi.org/10.1371/journal.pone.0241044

25. Rižner T.L., Brožič P., Doucette C., Turek-Etienne T., Müller-Vieira U., Sonneveld E., et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011; 76 (6): 607–15. DOI: https://doi.org/10.1016/j.steroids.2011.02.043 Epub 2011 Mar 08. PMID: 21376746.

26. Yang W., Chi H., Yang R., Lui P., Li R., Qiao J. Congenital anomalies after first-trimester dydrogesterone therapy during in vitro fertilization. Fertil Steril. 2023; 120 (4S): E72. DOI: https://doi.org/10.1016/j.fertnstert.2023.08.222

27. Katalinic A., Noftz M.R., Garcia-Velasco J.A., Shulman L.P., van den Anker J.N., Strauss Iii J.F. No additional risk of congenital anomalies after first-trimester dydrogesterone use: a systematic review and meta-analysis. Hum Reprod Open. 2024; 2024 (1): hoae004.

28. Serov V.N., Nazarenko T.A., Tapil’skaya N.I., Tetruashvili N.K., Shikh E.V. Progestogens safety in the treatment of infertility and during pregnancy: new data in 2023. Position of the Russian Society of Obstetricians and Gynecologists. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2023; (8): 236–9. DOI: https://doi.org/10.18565/aig.2023.196 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)